DEVELOPMENT JOURNEY TO REPLACE NEURONS LOST TO ALZHEIMER’S DISEASE WITH NEURAL PRECURSOR CELLS DERIVED FROM SKIN CELLS
With
Professor Michael Valenzuela,
Founder and Chief Scientific Officer,
Skin2Neuron
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Sydney | June 2026
Professor Michael Valenzuela is a science opinion leader, innovator and creative thinker with a career-long commitment to the prevention and treatment of dementia.
He studied psychology at the University of New South Wales (UNSW) before completing a PhD on Cognitive Reserve. This work was recognised by one of the nation’s top awards, the Australian Museum Eureka Prize for Medical Research.
Following that he completed graduate medicine and medical training at the Prince of Wales Hospital. In 2012, he established the Regenerative Neuroscience Group at the University of Sydney, and in 2017 became the university’s first Professor of Regenerative Medicine.
Professor Valenzuela’s group discovered a new cell type with potential for regenerative medicine, a rare neural precursor cell found deep within the human hair follicle. He is the main inventor on several related patents and is the Founder and Chief Scientific Officer of Skin2Neuron – a biotech company developing the first neurorestorative cell therapy for Alzheimer’s disease based on this work.
Between 2019-2021 he was employed as a senior advisor to the WHO in one of its flagship Decade of Healthy Ageing initiatives. He also joined the Centre for Healthy Brain Ageing at UNSW as Visiting Professor and played a leading role in the design and successful completion of the Maintain Your Brain – the world’s largest dementia prevention trial that found it is possible to delay cognitive decline in older at-risk people by about 1-year.
Professor Valenzuela is a frequent media commentator and author of the popular science book Maintain Your Brain.
Source: Supplied
You Might also like
-
Closing the diagnostic gap in ovarian cancer detection
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.
-
Space Health & Medicine on Australia’s Clinical Launchpad
Professor Smart is a veteran, medical doctor, health leader, aerospace medicine specialist, and retired Royal Australian Air Force (RAAF) senior officer. She is currently at the Professor, Military and Aerospace Medicine at the Australian National University (ANU), and serves as the Interim Director of the ANU Defence Institute, and as a Mission Specialist at the ANU Institute for Space. She previously served as the University’s COVID-19 Public Health Lead from 2020 to 2022.
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.